Wells Fargo & Company Aligos Therapeutics, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.64 - $1.13 $3 - $5	5 Added 1.71%	298 $0
Q4 2023 Feb 09, 2024	BUY	$0.56 - $0.8 $54 - $78	98 Added 50.26%	293 $0
Q3 2023 Nov 13, 2023	SELL	$0.71 - $1.06 $2 - $3	-3 Reduced 1.52%	195 $0
Q2 2023 Aug 15, 2023	BUY	$0.89 - $1.36 $19 - $29	22 Added 12.5%	198 $0
Q1 2023 May 12, 2023	BUY	$0.87 - $2.11 $2 - $6	3 Added 1.73%	176 $0
Q4 2022 Feb 13, 2023	BUY	$0.89 - $28.0 $3 - $112	4 Added 2.37%	173 $0
Q3 2022 Nov 14, 2022	BUY	$1.06 - $27.5 $46 - $1,210	44 Added 35.2%	169 $0
Q2 2022 Aug 12, 2022	SELL	$1.04 - $2.14 $965 - $1,985	-928 Reduced 88.13%	125 $0
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $15,620 - $91,622	-7,510 Reduced 87.7%	1,053 $2,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $98,303 - $151,479	8,563 New	8,563 $101,000
Q2 2021 Aug 16, 2021	SELL	$20.3 - $33.6 $66,360 - $109,838	-3,269 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$19.1 - $34.94 $37,798 - $69,146	-1,979 Reduced 37.71%	3,269 $74,000
Q4 2020 Feb 09, 2021	BUY	$13.2 - $32.74 $69,273 - $171,819	5,248 New	5,248 $145,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.